NBIX vs TXO · P/E 45, rev $1.77B vs rev $401.0M
Neurocrine Biosciences Inc (NBIX) versus MorningStar Partners, L.P. (TXO) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
MorningStar Partners, L.P. (TXO) is a oil & gas e&p company listed on NYSE.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported TXO revenue for 2025-12-31 was $401.0M. Net income was -$21.6M. Revenue was up 41.8% from 2024-12-31 to 2025-12-31. TXO currently screens at market cap $693.8M.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. TXO currently screens at market cap $693.8M.
Not investment advice. Open the NBIX and TXO stock pages for the full models.
Not investment advice.